Trending Stock News

$-0.08 EPS Expected for BioTime, Inc. (BTX); 1 Analysts Are Bullish Mitel Networks (MITL) Last Week

Mitel Networks Corporation (NASDAQ:MITL) Logo

Analysts expect BioTime, Inc. (NYSEAMERICAN:BTX) to report $-0.08 EPS on May, 9.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.08 EPS. After having $-0.08 EPS previously, BioTime, Inc.’s analysts see 0.00% EPS growth. The stock increased 0.61% or $0.015 during the last trading session, reaching $2.485. About 117,694 shares traded. BioTime, Inc. (NYSEAMERICAN:BTX) has declined 25.77% since April 18, 2017 and is downtrending. It has underperformed by 37.32% the S&P500.

Among 4 analysts covering Mitel Networks (NASDAQ:MITL), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. Mitel Networks had 16 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Mitel Networks Corporation (NASDAQ:MITL) earned “Outperform” rating by RBC Capital Markets on Tuesday, November 3. The stock has “Hold” rating by RBC Capital Markets on Tuesday, July 25. The rating was maintained by RBC Capital Markets on Friday, October 9 with “Outperform”. The company was upgraded on Thursday, July 27 by National Bank Canada. The firm earned “Sector Perform” rating on Tuesday, December 20 by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, August 7. The firm has “Sell” rating given on Tuesday, August 18 by Zacks. The stock of Mitel Networks Corporation (NASDAQ:MITL) earned “Hold” rating by National Bank Canada on Wednesday, April 11. On Tuesday, August 25 the stock rating was upgraded by Zacks to “Sell”. The firm earned “Sell” rating on Thursday, September 17 by Zacks. See Mitel Networks Corporation (NASDAQ:MITL) latest ratings:

11/04/2018 Broker: National Bank Canada Rating: Hold Downgrade
16/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $9.5 Maintain
14/12/2017 Broker: Craig Hallum Rating: Buy New Target: $14 Initiates Coverage On

Investors sentiment increased to 2.62 in Q4 2017. Its up 0.66, from 1.96 in 2017Q3. It improved, as 5 investors sold BioTime, Inc. shares while 16 reduced holdings. 21 funds opened positions while 34 raised stakes. 57.90 million shares or 17.85% more from 49.13 million shares in 2017Q3 were reported. Artal Grp Inc Sa reported 1.56 million shares. Family Management Corporation owns 32,540 shares. 11,389 are held by Amalgamated Retail Bank. Parametric Portfolio Assoc invested in 14,120 shares or 0% of the stock. Citigroup accumulated 0% or 13,899 shares. Alliancebernstein L P holds 0% or 87,000 shares in its portfolio. 32,496 are owned by Voya Investment Management Limited. Pnc Svcs Group Incorporated Inc holds 0% or 300 shares. Macquarie Gru Ltd owns 3,800 shares. The Alabama-based Regions Corp has invested 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Sg Americas Ltd holds 0% or 62,301 shares in its portfolio. Axa, a France-based fund reported 2.30M shares. Art Advisors Limited Co accumulated 100,126 shares. Jane Street Grp Ltd Liability reported 38,991 shares. Savings Bank Of Mellon Corporation invested in 658,373 shares or 0% of the stock.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $315.27 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It currently has negative earnings. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *